Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-IGF1R)1Ramo
• Allele Name: transgene insertion 1, Roger A Moorehead
• Allele ID: MGI:5432255
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-IGF1R)1Ramo/0	involves: 129 * C57BL/6 * FVB	MGI:7266256
cx2	Tg(MMTV-rtTA)1Lach/0 Tg(tetO-IGF1R)1Ramo/0	involves: FVB	MGI:5432258
cx3	Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-IGF1R)1Ramo/0	involves: FVB	MGI:7265160

Genotype
MGI:7266256

cx1

• Allelic Composition: Tg(Scgb1a1-rtTA)1Jaw/0; Tg(tetO-IGF1R)1Ramo/0
• Genetic Background: involves: 129 * C57BL/6 * FVB

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased lung tumor incidence ( J:271820 )

• mice administered doxycyline beginning at 21 days of age develop tumors on the lung surface as early as 90 days after doxycycline treatment

• most mice treated with doxycycline for up to 9 months exhibit visible lung tumors (2-30 tumors); tumors show multifocal adenomatous alveolar hyperplasia with papillary and solid adenomas

• mice in which doxycycline is removed after an 8-month treatment period show incomplete tumor regression

• however, bronchiolar hyperplasia is not seen in doxycycline treated mice

increased lung adenoma incidence ( J:271820 )

• solid adenomas are seen in doxycycline-treated mice

respiratory system

increased lung tumor incidence ( J:271820 )

• mice administered doxycyline beginning at 21 days of age develop tumors on the lung surface as early as 90 days after doxycycline treatment

• most mice treated with doxycycline for up to 9 months exhibit visible lung tumors (2-30 tumors); tumors show multifocal adenomatous alveolar hyperplasia with papillary and solid adenomas

• mice in which doxycycline is removed after an 8-month treatment period show incomplete tumor regression

• however, bronchiolar hyperplasia is not seen in doxycycline treated mice

increased lung adenoma incidence ( J:271820 )

• solid adenomas are seen in doxycycline-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:271820

Genotype
MGI:5432258

cx2

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(tetO-IGF1R)1Ramo/0
• Genetic Background: involves: FVB

neoplasm

increased mammary gland tumor incidence ( J:121069 )

• mutants maintained on doxycycline for an extended period of time develop mammary tumors with an average latency of 78 days

• doxycycline-treated mutants typically develop one or two tumors in the first or second/third mammary glands with hyperplastic nodules in the other mammary glands

• small mammary lesions are primarily composed of solid sheets of tumor cells with sparse stroma

• larger tumors are more heterogeneous in appearance, with tumors displaying features of adenosquamous carcinoma, adenomyoepithelioloma, and glandular adenocarcinoma

increased mammary adenocarcinoma incidence ( J:121069 )

• larger tumors display features of adenosquamous carcinoma and glandular adenocarcinoma

endocrine/exocrine glands

abnormal mammary gland development ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age exhibit impaired mammary ductal development

abnormal branching of the mammary ductal tree ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age show a delay in ductal elongation and in some cases the duct remains behind in the lymph node compared to controls in which ductal structure almost completely fills the mammary fat pad

abnormal mammary gland epithelium morphology ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age exhibit mammary epithelial hyperplasia

increased mammary gland tumor incidence ( J:121069 )

• mutants maintained on doxycycline for an extended period of time develop mammary tumors with an average latency of 78 days

• doxycycline-treated mutants typically develop one or two tumors in the first or second/third mammary glands with hyperplastic nodules in the other mammary glands

• small mammary lesions are primarily composed of solid sheets of tumor cells with sparse stroma

• larger tumors are more heterogeneous in appearance, with tumors displaying features of adenosquamous carcinoma, adenomyoepithelioloma, and glandular adenocarcinoma

increased mammary adenocarcinoma incidence ( J:121069 )

• larger tumors display features of adenosquamous carcinoma and glandular adenocarcinoma

mammary gland hyperplasia ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age exhibit mammary epithelial hyperplasia

integument

abnormal mammary gland development ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age exhibit impaired mammary ductal development

abnormal branching of the mammary ductal tree ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age show a delay in ductal elongation and in some cases the duct remains behind in the lymph node compared to controls in which ductal structure almost completely fills the mammary fat pad

abnormal mammary gland epithelium morphology ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age exhibit mammary epithelial hyperplasia

increased mammary gland tumor incidence ( J:121069 )

• mutants maintained on doxycycline for an extended period of time develop mammary tumors with an average latency of 78 days

• doxycycline-treated mutants typically develop one or two tumors in the first or second/third mammary glands with hyperplastic nodules in the other mammary glands

• small mammary lesions are primarily composed of solid sheets of tumor cells with sparse stroma

• larger tumors are more heterogeneous in appearance, with tumors displaying features of adenosquamous carcinoma, adenomyoepithelioloma, and glandular adenocarcinoma

increased mammary adenocarcinoma incidence ( J:121069 )

• larger tumors display features of adenosquamous carcinoma and glandular adenocarcinoma

mammary gland hyperplasia ( J:121069 )

♀ • 55 day old mutants induced with doxycycline beginning at 21 days of age exhibit mammary epithelial hyperplasia

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:121069

Genotype
MGI:7265160

cx3

• Allelic Composition: Tg(SFTPC-rtTA)5Jaw/0; Tg(tetO-IGF1R)1Ramo/0
• Genetic Background: involves: FVB

neoplasm

increased lung tumor incidence ( J:271820 )

• mice administered doxycyline beginning at 21 days of age develop tumors on the lung surface as early as 90 days after doxycycline treatment

• most mice treated with doxycycline for up to 9 months exhibit visible lung tumors (2-30 tumors); tumors show multifocal adenomatous alveolar hyperplasia with papillary and solid adenomas

• mice in which doxycycline is removed after an 8-month treatment period show incomplete tumor regression

• however, bronchiolar hyperplasia is not seen in doxycycline treated mice

increased lung adenoma incidence ( J:271820 )

• solid adenomas are seen in doxycycline-treated mice

respiratory system

increased lung tumor incidence ( J:271820 )

• mice administered doxycyline beginning at 21 days of age develop tumors on the lung surface as early as 90 days after doxycycline treatment

• most mice treated with doxycycline for up to 9 months exhibit visible lung tumors (2-30 tumors); tumors show multifocal adenomatous alveolar hyperplasia with papillary and solid adenomas

• mice in which doxycycline is removed after an 8-month treatment period show incomplete tumor regression

• however, bronchiolar hyperplasia is not seen in doxycycline treated mice

increased lung adenoma incidence ( J:271820 )

• solid adenomas are seen in doxycycline-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung cancer		DOID:1324	OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210	J:271820